Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pan-tumor × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 165 Carcinoma, Non-Small-Cell Lung 76 Breast Neoplasms 62 Neoplasms 57 Ovarian Neoplasms 50 Glioblastoma 37 Carcinoma, Hepatocellular 29 Neoplasm Metastasis 28 Colonic Neoplasms 25 Fallopian Tube Neoplasms 21 Carcinoma, Renal Cell 20 Uterine Cervical Neoplasms 18 Rectal Neoplasms 16 Pancreatic Neoplasms 15 Stomach Neoplasms 14 Liver Neoplasms 13 Brain Neoplasms 13 Non-Squamous Non-Small Cell Lung Cancer 12 Lung Neoplasms 11 Recurrence 10 Glioma 10 Endometrial Neoplasms 10 Carcinoma, Ovarian Epithelial 10 Advanced Solid Tumors 9 Triple Negative Breast Neoplasms 8 Melanoma 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Gastrointestinal Neoplasms 7 Solid Cancers 6 Small Cell Lung Carcinoma 6

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡